rs45589637
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_032043.3(BRIP1):c.2220G>T(p.Gln740His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000575 in 1,613,890 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_032043.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BRIP1 | NM_032043.3 | c.2220G>T | p.Gln740His | missense_variant | 15/20 | ENST00000259008.7 | NP_114432.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRIP1 | ENST00000259008.7 | c.2220G>T | p.Gln740His | missense_variant | 15/20 | 1 | NM_032043.3 | ENSP00000259008 | P2 |
Frequencies
GnomAD3 genomes AF: 0.000506 AC: 77AN: 152100Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000537 AC: 135AN: 251286Hom.: 0 AF XY: 0.000434 AC XY: 59AN XY: 135822
GnomAD4 exome AF: 0.000582 AC: 851AN: 1461672Hom.: 0 Cov.: 31 AF XY: 0.000556 AC XY: 404AN XY: 727138
GnomAD4 genome AF: 0.000506 AC: 77AN: 152218Hom.: 0 Cov.: 32 AF XY: 0.000511 AC XY: 38AN XY: 74434
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:5
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2024 | BRIP1: BP4, BS1 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden | Nov 03, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Apr 20, 2023 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 02, 2016 | Variant summary: The BRIP1 c.2220G>T (p.Gln740His) variant involves the alteration of a non-conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 58/133810 control chromosomes at a frequency of 0.0004335, which is approximately 7 times the estimated maximal expected allele frequency of a pathogenic BRIP1 variant (0.0000625), suggesting this variant is likely a benign polymorphism. This variant has been reported in multiple cancer patients, however, a case-control study showed that this variant was not associated with breast cancer (OR=0.638, P=0.49, Haiman_2013). In addition, two patients carry the variant of interest and a pathogenic variant, homozygous MUTYH c.1187G>A/p.Gly396Asp and PALB2 c.3113G>A/W1038X, respectively (Yurgelun_2015, Kahn_2016), suggesting the variant of interest may be benign. On the other hand, multiple clinical diagnostic laboratories/reputable databases classified this variant as uncertain significance. Taken together, this variant is classified as likely benign. - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Jul 28, 2020 | This variant is associated with the following publications: (PMID: 28202063, 31159747, 25980754, 24728327, 26534844, 27547810, 26315354, 28528518, 26921362, 27978560, 28678401, 28767289, 31822495, 32039725, 31658756, 33115781) - |
Likely benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 08, 2020 | - - |
Hereditary cancer-predisposing syndrome Uncertain:2Benign:3
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 15, 2020 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Nov 20, 2020 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | True Health Diagnostics | Apr 09, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneKor MSA | Aug 01, 2018 | - - |
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | Apr 11, 2021 | - - |
Fanconi anemia complementation group J Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 09, 2021 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Aug 23, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Mar 18, 2019 | This variant was classified as: Uncertain significance. The available evidence on this variant's pathogenicity is insufficient or conflicting. The following ACMG criteria were applied in classifying this variant: PP3,BP1. - |
Familial cancer of breast Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Mar 02, 2023 | This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jan 01, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Jun 15, 2021 | ACMG classification criteria: BS1 strong - |
not specified Uncertain:2Other:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Apr 20, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Jul 31, 2024 | - - |
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
BRIP1-related disorder Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 05, 2019 | The BRIP1 c.2220G>T (p.Gln740His) missense variant has been reported in at least four studies in which it is found in a heterozygous state in total of three individuals with Lynch syndrome, one of whom also carried a homozygous variant in the MUTYH gene (Bodian et al. 2014; Ramus et al. 2015; Yurgelun et al. 2015; Easton et al. 2016). The p.Gln740His variant was identified in a heterozygous state in six of 3431 controls and is reported at a frequency of 0.00140 in the Latino population of the Genome Aggregation Database. Based on the limited evidence, the p.Gln740His variant is classified as a variant of unknown significance but suspicious for pathogenicity for BRIP1-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 17, 2023 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Benign:1Other:1
not provided, no classification provided | phenotyping only | GenomeConnect - Invitae Patient Insights Network | - | Variant interpreted as Likely benign and reported on 10-31-2019 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Malignant tumor of breast Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The BRIP1 p.Gln740His variant was identified in 32 of 48608 proband chromosomes (frequency: 0.0007) from individuals or families with breast, ovarian cancer or Lynch syndrome and was present in 7 of 14818 control chromosomes (frequency: 0.0006) from healthy individuals (Easton 2016, Jalkh 2017, Li 2015, Penkert 2018, Ramus 2015, Tung 2015, Yurgelun 2015). The variant was also identified in dbSNP (ID: rs45589637) as "With other allele", ClinVar (classified as uncertain significance by Invitae, Ambry Genetics and nine other submitters; as likely benign by Integrated Genetics/Laboratory Corporation of America and GeneDx). The variant was identified in control databases in 144 of 277004 chromosomes at a frequency of 0.0005 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 2 of 24024 chromosomes (freq: 0.00008), Other in 4 of 6460 chromosomes (freq: 0.0006), Latino in 48 of 34414 chromosomes (freq: 0.001), European in 82 of 126532 chromosomes (freq: 0.0007), Ashkenazi Jewish in 2 of 10148 chromosomes (freq: 0.0002), Finnish in 6 of 25780 chromosomes (freq: 0.0002); it was not observed in the East Asian, and South Asian populations. The p.Gln740 residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and 2 of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Ovarian neoplasm Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Aug 23, 2016 | - - |
Breast and/or ovarian cancer Benign:1
Likely benign, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Nov 02, 2022 | - - |
Hereditary cancer Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Mendelics | Jan 23, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at